Valeant Pharma (NYSE: VRX) reported Q2 EPS of $1.91, versus $1.34 reported last year. Revenue for the quarter came in at $1.99 billion, versus $1.06 billion reported last year.

For earnings history and earnings-related data on Valeant Pharma (VRX) click here.